Metastatic Colorectal Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
- Published Date : August 15, 2026
- Updated On : October 18, 2026
- Pages : 53
Metastatic Colorectal Cancer Emerging Therapy and TPP Insights
Thelansis’s “Metastatic Colorectal Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Metastatic Colorectal Cancer Overview
Metastatic colorectal cancer (mCRC) is colorectal adenocarcinoma that has spread beyond the bowel, commonly to the liver, lungs, or peritoneum. Symptoms may include altered bowel habits, rectal bleeding, abdominal pain, anemia, or weight loss. Treatment is guided by fitness, tumor sidedness, disease burden, and molecular profile. Options include fluoropyrimidine-based chemotherapy with bevacizumab or an anti-EGFR antibody for suitable RAS-wild-type disease; selected patients with limited metastases may benefit from surgery or local treatment. Testing for MMR/MSI, RAS, BRAF, HER2, and rare gene fusions informs therapy. Immunotherapy is effective in MSI-H/dMMR tumors, while targeted options are available for selected BRAF V600E, KRAS G12C, HER2-positive, and fusion-positive cancers. In the United States in 2026, encorafenib with cetuximab and fluorouracil-based chemotherapy received FDA traditional approval for first-line BRAF V600E mCRC. Resistance and relapse remain major challenges.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Metastatic Colorectal Cancer Emerging Therapy and TPP Insights
Thelansis’s “Metastatic Colorectal Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Metastatic Colorectal Cancer Overview
Metastatic colorectal cancer (mCRC) is colorectal adenocarcinoma that has spread beyond the bowel, commonly to the liver, lungs, or peritoneum. Symptoms may include altered bowel habits, rectal bleeding, abdominal pain, anemia, or weight loss. Treatment is guided by fitness, tumor sidedness, disease burden, and molecular profile. Options include fluoropyrimidine-based chemotherapy with bevacizumab or an anti-EGFR antibody for suitable RAS-wild-type disease; selected patients with limited metastases may benefit from surgery or local treatment. Testing for MMR/MSI, RAS, BRAF, HER2, and rare gene fusions informs therapy. Immunotherapy is effective in MSI-H/dMMR tumors, while targeted options are available for selected BRAF V600E, KRAS G12C, HER2-positive, and fusion-positive cancers. In the United States in 2026, encorafenib with cetuximab and fluorouracil-based chemotherapy received FDA traditional approval for first-line BRAF V600E mCRC. Resistance and relapse remain major challenges.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
